ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma

In ReNeu, the largest multicenter NF1-PN trial reported to date, mirdametinib treatment demonstrated significant confirmed ORRs by BICR, deep and durable PN volume reductions, and early, sustained, and clinically meaningful improvement in pain and HRQOL. Mirdametinib was well-tolerated in adults and children.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2024-11-08
DOI
https://doi.org/10.1200/jco.24.01034
Citations
74
Primary Topic
Neurofibromatosis and Schwannoma Cases
Type
article
Field-Weighted Citation Impact
27.31

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma

Kevin Bielamowicz, Carl Koschmann, Rene McNall‐Knapp, Jamie K. Capal et al.
74 citations
Journal of Clinical Oncology
Neurofibromatosis and Schwannoma Cases
27.31
article

ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma

Kevin Bielamowicz, Carl Koschmann, Rene McNall‐Knapp, Jamie K. Capal, Prakash Ambady, Brian Andrew Van Tine, Raju Antony, Hans Shuhaiber, Ana Aguilar-Bonilla, Miriam Bornhorst, L. Mary Smith, Maciej M. Mrugała, Cynthia Campen, Punita Gupta, Laura J. Klesse, Alpa Sidhu, Stefania Maraka, Nathan Robison, Nicholas K. Foreman, David Schiff, Tobias Walbert, Ahmed M. Raslan, Ryan D. Roberts, Armend Lokku, John M. Slopis, Michael Weber, Zsila Sadighi, Angela C. Hirbe, Phioanh Leia Nghiemphu, David H. Viskochil, Lauren Weintraub, Daniela A. Bota, Jonathan Gill, Lindsay Kilburn, Laura K. Metrock, Reuben Antony, Julia Meade, Sarah Chagnon, Andrea Franson, Radhika Dhamija, Nagma Dalvi, Dusica Babovic‐Vuksanovic, Kathryn Nevel, Paul L. Moots, Stacie Stapleton, Fouad Hajjar, Gurcharanjeet Kaur, Leia Nghiemphu, Ryan Merrell, Timothy R. Gershon, Christopher L. Moertel, Andrew Walter, Mary Lou Schmidt, Ziad Khatib
article en
74 citations

Abstract

In ReNeu, the largest multicenter NF1-PN trial reported to date, mirdametinib treatment demonstrated significant confirmed ORRs by BICR, deep and durable PN volume reductions, and early, sustained, and clinically meaningful improvement in pain and HRQOL. Mirdametinib was well-tolerated in adults and children.

Journal of Clinical OncologyVol. 43(6)
Indiana University Health (US), Morgan Stanley Children's Hospital (US), Arkansas Children's Hospital (US), University of Minnesota (US), Nationwide Children's Hospital (US), Lucile Packard Children's Hospital (US), Montefiore Medical Center (US), Children's National (US), Children's Hospital of Los Angeles (US), The University of Texas MD Anderson Cancer Center (US), Johns Hopkins University (US), Orlando Health (US), Emory University (US), University of California, Los Angeles (US), Oregon Health & Science University (US), University of Pittsburgh (US), Wayne State University (US), University of California, Irvine (US), Washington University in St. Louis (US), University of Utah (US), University of Michigan (US), Columbia University Irving Medical Center (US), University of Iowa Hospitals and Clinics (US), University of Alabama at Birmingham (US), University of Florida (US), University of Illinois Chicago (US), Children's Hospital Colorado (US), Johns Hopkins All Children's Hospital (US), AdventHealth for Children (US), Mayo Clinic in Arizona (US), St. Joseph’s University Medical Center (US), University of Virginia Medical Center (US), Children's Hospital at Montefiore (US), Children's Hospital of The King's Daughters (US), Meridien Research (US), Miami Children's Hospital (US), Indiana University School of Medicine, University of Oklahoma Health Sciences Center (US), Indiana University – Purdue University Indianapolis (US), Albany Medical Center Hospital (US), University of Arkansas for Medical Sciences (US), University of California, Davis (US), The University of Texas Southwestern Medical Center (US), Michigan State University (US), Vanderbilt University Medical Center (US), University of Colorado Denver (US)
AstraZeneca, Alexion Pharmaceuticals, Deutsches Krebsforschungszentrum, Jazz Pharmaceuticals, Springworks Therapeutics, Servier, SymBio Pharmaceuticals Limited, National Cancer Institute
Openalex Percentile: Top 0%
Neurofibromatosis and Schwannoma Cases
27.31
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.